Tolevamer for clostridium difficile associate diarrhoea
Please note that following on from information provided to NICE by the company in May 2014, the appraisal of Tolevamer for clostridium difficile associated diarrhoea [ID378] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
ID number 378
Referral date 01 June 2007
Topic area
  • Digestive system

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC

Project Team

Assessment Group / Evidence Review Group: TBC
Communications manager: TBC
Executive Lead: Gillian Leng
Project manager: TBC

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
23 January 2023 Discontinued. Please note that following on from information provided to NICE by the company in May 2014, the appraisal of Tolevamer for clostridium difficile associated diarrhoea [ID378] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
14 May 2014

As you will be aware, the Department of Health has asked the Institute to conduct an appraisal of tolevamer for clostridium difficile..

Following an update on the regulatory status of this technology, the manufacturer has informed us that development on tolevamer for clostridium difficile has stopped and there are no plans to seek regulatory approval. Therefore, the appraisal remains suspended.

As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes.


For further information on our processes and methods, please see our CHTE processes and methods manual